Cancer patients on targeted therapy get extended safety monitoring

NCT ID NCT03340506

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over time. Participants must have completed the main goals of their earlier study and be judged by their doctor as likely to benefit from ongoing treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma lung neoplasm malignant glioma melanoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH GRADE GLIOMA MELANOMA NON-SMALL CELL LUNG CANCER RARE CANCERS SOLID TUMOR

Contacts and locations

Locations

Honor Health Research Institute
ACTIVE_NOT_RECRUITING

Scottsdale, Arizona, 85258, United States
James Cancer Hospital and Solove Research Institute Ohio State
COMPLETED

Columbus, Ohio, 43210, United States
Mary Crowley Cancer Research
COMPLETED

Dallas, Texas, 75251, United States
National Institute Of Health
ACTIVE_NOT_RECRUITING

Bethesda, Maryland, 20892, United States
Novartis Investigative Site
COMPLETED

Caba, Buenos Aires, C1121ABE, Argentina
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Innsbruck, Tyrol, 6020, Austria
Novartis Investigative Site
COMPLETED

Beijing, 100036, China
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Copenhagen, DK-2100, Denmark
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Lyon, 69373, France
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Nantes, 44093, France
Novartis Investigative Site
RECRUITING

Paris, 75231, France
Novartis Investigative Site
COMPLETED

Paris, 75970, France
Novartis Investigative Site
COMPLETED

Villejuif, 94800, France
Novartis Investigative Site
COMPLETED

Mannheim, Baden-Wurttemberg, 68305, Germany
Novartis Investigative Site
COMPLETED

Berlin, 13353, Germany
Novartis Investigative Site
RECRUITING

Essen, 45147, Germany
Novartis Investigative Site
COMPLETED

Hamburg, 20246, Germany
Novartis Investigative Site
RECRUITING

Hamburg, 20246, Germany
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Heidelberg, 69120, Germany
Novartis Investigative Site
COMPLETED

Debrecen, Hajdu Bihar Megye, 4032, Hungary
Novartis Investigative Site
COMPLETED

Budapest, H 1122, Hungary
Novartis Investigative Site
COMPLETED

Kashiwa, Chiba, 277-8577, Japan
Novartis Investigative Site
COMPLETED

Chuo Ku, Tokyo, 1040045, Japan
Novartis Investigative Site
COMPLETED

Rotterdam, South Holland, 3015 GD, Netherlands
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Utrecht, 3584 CX, Netherlands
Novartis Investigative Site
RECRUITING

Barcelona, 08035, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28009, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28040, Spain
Novartis Investigative Site
COMPLETED

Madrid, 28041, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28050, Spain
Novartis Investigative Site
RECRUITING

Valencia, 46026, Spain
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Songkhla, Hat Yai, 90110, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.